Skip to main content
. 2022 Oct 25;10(10):e005635. doi: 10.1136/jitc-2022-005635

Figure 1.

Figure 1

Identification of patients assigned to the immune checkpoint inhibitor group. Flow chart describing the identification and selection process of the 27 patients assigned to the immune checkpoint inhibitor (ICI) group. Swissmedic is the Swiss authority responsible for the approval as well as the surveillance of the efficacy and safety of drugs. IrAE, immune-related adverse event; IrC, immune-related cholangitis; IrH, immune-related hepatitis; PD-1, programmed cell death 1, PD-L1, programmed cell death ligand 1.